Oaktop Capital Management II’s Accelerate Diagnostics AXDX Stock Holding History

Oaktop Capital Management II’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,500	Closed	-$1.18M	–	18
2020 Q4	$1.18M	Hold	15,500	–	–	0.21%	17
2020 Q3	$1.65M	Hold	15,500	–	–	0.37%	17
2020 Q2	$2.35M	Hold	15,500	–	–	0.55%	16
2020 Q1	$1.29M	Hold	15,500	–	–	0.4%	18
2019 Q4	$2.62M	Hold	15,500	–	–	0.69%	14
2019 Q3	$2.88M	Hold	15,500	–	–	0.59%	13
2019 Q2	$3.55M	Hold	15,500	–	–	0.76%	14
2019 Q1	$3.26M	Hold	15,500	–	–	0.68%	14
2018 Q4	$1.78M	Hold	15,500	–	–	0.5%	14
2018 Q3	$3.56M	Hold	15,500	–	–	0.79%	14
2018 Q2	$3.46M	Hold	15,500	–	–	0.76%	14
2018 Q1	$3.54M	Hold	15,500	–	–	0.74%	14
2017 Q4	$4.06M	Hold	15,500	–	–	0.82%	14
2017 Q3	$3.48M	Hold	15,500	–	–	0.58%	16
2017 Q2	$4.24M	Hold	15,500	–	–	0.78%	16
2017 Q1	$3.75M	Buy	15,500 +2,500	+19%	+$571K	0.74%	16
2016 Q4	$2.7M	Buy	13,000 +500	+4%	+$119K	0.59%	16
2016 Q3	$3.41M	Hold	12,500	–	–	0.8%	16
2016 Q2	$1.8M	Buy	+12,500	New	+$1.68M	0.44%	16

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Oaktop Capital Management II's AXDX Position: Q1 2021 in Review

Oaktop Capital Management II sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 15,500 shares — an estimated $1.18M sold.

Oaktop Capital Management II first reported a position in AXDX in Q2 2016 and held it in 19 quarters. The position peaked at $4.24M in Q2 2017. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

Oaktop Capital Management II reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
Oaktop Capital Management II sold 15,500 Accelerate Diagnostics shares in Q1 2021, an estimated $1.18M.
Oaktop Capital Management II first reported a position in Accelerate Diagnostics in Q2 2016 and held it in 19 quarters.
Oaktop Capital Management II's Accelerate Diagnostics position peaked at $4.24M in Q2 2017.
99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Oaktop Capital Management II's 13F filing for Q1 2021, filed 17 May 2021.